0001181431-12-061038.txt : 20121129 0001181431-12-061038.hdr.sgml : 20121129 20121129134628 ACCESSION NUMBER: 0001181431-12-061038 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121127 FILED AS OF DATE: 20121129 DATE AS OF CHANGE: 20121129 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CHASE ANTHONY R CENTRAL INDEX KEY: 0001223756 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 121231209 MAIL ADDRESS: STREET 1: 10307 PACIFIC CENTER COURT CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY STREET 2: SUITE 101 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425-354-5038 MAIL ADDRESS: STREET 1: 3450 MONTE VILLA PARKWAY STREET 2: SUITE 101 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 rrd361572.xml X0306 4 2012-11-27 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001223756 CHASE ANTHONY R 3450 MONTE VILLA PARKWAY, SUITE 101 BOTHELL WA 98021 1 0 0 0 Common Stock 2012-11-27 4 S 0 1100 29.0368 D 26144 D Common Stock 2012-11-28 4 S 0 1600 28.1681 D 24544 D Common Stock 2012-11-28 4 S 0 5700 29.7002 D 18844 D Common Stock 2012-11-28 4 S 0 1600 30.2056 D 17244 D This transaction was executed in multiple trades in prices ranging from $29.00 to $29.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $27.79 to $28.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $29.35 to $29.95, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $30.00 to $30.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. /s/ Anthony R. Chase 2012-11-28